Skip to main content
HYUNDAI PHARMACEUTICAL CO., LTD logo

HYUNDAI PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 004310 ISIN · KR7004310009 KO Manufacturing
Open in API
Filings indexed 184 across all filing types
Latest filing 2020-02-18 Audit Report / Informat…
Country KR South Korea
Listing KO 004310

About HYUNDAI PHARMACEUTICAL CO., LTD

http://www.hyundaipharm.co.kr/english

HYUNDAI PHARMACEUTICAL CO., LTD. is a company engaged in the research, development, manufacturing, and distribution of pharmaceutical products, medical devices, and health-focused food and beverages. The company's portfolio encompasses a broad range of prescription (ETC) and over-the-counter (OTC) medicines. Key therapeutic areas include dermatology, respiratory and gastrointestinal disorders, as well as treatments for conditions such as hypertension and dementia. With a strong commitment to innovation, the company focuses on the research of new substances and the continuous development of its drug pipeline. It also serves as a strategic partner for global companies, facilitating market entry and collaboration through its business development initiatives.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 98% confidence The document is a regulatory filing titled '감사보고서 제출' (Submission of Audit Report) by Hyundai Pharm. It provides a summary of the audit opinion, financial highlights (assets, liabilities, revenue, profit), and the name of the external auditor. While it contains financial data, it is a standalone regulatory disclosure of the audit report submission rather than the full annual report (10-K) or a comprehensive interim report. Given the specific nature of audit report disclosures in the Korean regulatory context, it fits best under the Audit Report (AR) category. FY 2019
2020-02-18 Korean
투자판단관련주요경영사항(전기 회계오류 수정)
Audit Report / Information Classification · 95% confidence The document is a regulatory filing from Hyundai Pharm regarding a correction of accounting errors in previous financial statements. It details the nature of the error (sales incentive estimation), the impact on financial statements, and the company's plan for re-audit. Since it is a specific regulatory disclosure regarding financial reporting adjustments and does not fit into standard categories like 10-K or IR, it is classified as a general regulatory filing. FY 2018
2020-02-18 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Hyundai Pharm regarding a decision on cash dividends. It specifies the dividend amount per share, the dividend record date, the total dividend amount, and the scheduled date for the general meeting of shareholders to approve the dividend. This fits the definition of a 'Notice of Dividend Amount' (DIV).
2020-01-31 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Hyundai Pharm. It outlines the date, location, and agenda items for the upcoming meeting, including the approval of financial statements, amendments to the articles of incorporation, and the appointment of directors. This type of document is a standard proxy solicitation and information statement provided to shareholders to inform them of meeting details and agenda items, which falls under the Proxy Solicitation & Information Statement category.
2020-01-31 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Hyundai Pharm Co., Ltd. It contains the meeting agenda, proposed resolutions (such as financial statement approval, articles of incorporation changes, and director appointments), and detailed management information regarding business performance and financial statements. This document is a formal proxy statement/notice sent to shareholders to inform them of the upcoming meeting and solicit their votes. In the context of the provided categories, this aligns with 'Proxy Solicitation & Information Statement' (PSI).
2020-01-31 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Management Reports Classification · 95% confidence The document is a regulatory filing from Hyundai Pharm regarding a significant change in sales or profit structure (30% or more). It provides preliminary financial results (revenue, operating profit, net income) and explicitly states that these are tentative figures subject to change upon final audit. This type of disclosure is a standard regulatory requirement in the Korean market (DART system) for reporting material changes in financial performance, which falls under the 'Earnings Release' category as it provides key financial highlights before the full audit report is finalized.
2019-12-20 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.